Immunotherapy Duo Delays Disease Progression in Previously Untreated Patients With Melanoma: RELATIVITY-047

Source: The ASCO Post, March 2022

A novel immunotherapeutic combination that targets PD-1 and the LAG-3 pathway may significantly delay disease progression as a first-line treatment of advanced or unresectable melanoma. Updated results of the global phase III RELATIVITY-047 trial validated the study’s initial findings and were presented in the March 2022 session of the ASCO Plenary Series by Georgina V. Long, MD, PhD, of the Melanoma Institute Australia, Sydney (Abstract 360385).

In the study, nivolumab and relatlimab were given as a fixed-dose combination to 714 previously untreated patients with advanced or metastatic melanoma. Dr. Long reported updated findings for progression-free survival, as well as the first data on the secondary endpoints of overall survival and overall response rate.